Adding Immunotherapy to Chemotherapy After Surgery Improves Survival in Colon Cancer

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

Adjuvant Immunotherapy Ups Survival in dMMR Colon Cancer

(MedPage Today) -- CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, a large randomized trial...

Immune Checkpoint Inhibitors Boost Efficacy of Standard Chemotherapy in

In a groundbreaking advancement presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers from Dana-Farber Cancer Institute have unveiled compelling evidence demonstrating that the addition of an immune checkpoint inhibitor, atezolizumab, to the standard adjuvant chemotherapy regimen significantly enhances disease-free survival in patients with stage 3 colon cancer exhibiting deficient DNA mismatch repair (dM…

Recurrence or Risk of Death Reduced by 50% With Atezolizumab/Chemo in dMMR Colon Cancer

Results from the ATOMIC trial found a 50% reduction in the risk of death for patients with dMMR colon cancer receiving atezolizumab/chemotherapy.

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.